PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Annals of Gastroenterological Surgery0 citationsOpen Access

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

View Full Paper
TSTaihei SomaRARyo AshidaTKTakeshi Kawakami

Key Points

  • To evaluate the management of disappearing liver metastases after systemic chemotherapy and their long-term outcomes.
  • Reviewed patients undergoing hepatectomy after chemotherapy for initially unresectable colorectal liver metastases
  • Defined true complete response as either resected liver metastases with pathological response or unresected without recurrence
  • Compared long-term outcomes of patients with and without resection of all disappearing liver metastases
  • 70.8% of disappearing liver metastases achieved true complete response
  • Median recurrence-free survival was 11.1 months for resected and 7.6 months for non-resected groups, with no significant difference (p = 0.594)
  • Median overall survival was higher in non-resected groups (53.6 months) compared to resected groups (43.6 months), but not significantly different (p = 0.819)

Abstract

ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with pathological CR or unresected DLMs without local recurrence. Long‐term outcomes were compared between patients with and without resection of all DLMs. Results Among 58 patients, 26 (44.8%) had DLMs, totaling 106 lesions. True CR was achieved in 70.8% of DLM lesions. Long‐term outcomes did not differ between patients with and without resection of all DLMs (median recurrence‐free survival, 11.1 vs. 7.6 months, p = 0.594; median surgical failure‐free survival, 11.1 vs. 17.2 months, p = 0.758; median overall survival, 43.6 vs. 53.6 months, p = 0.819). DLM lesions with true CR had smaller initial diameters than those without true CR (5 vs. 9 mm, p = 0.013). Conclusion Regardless of whether all DLMs were resected, patients had acceptable long‐term outcomes. DLM lesions with a larger initial diameter before chemotherapy may warrant proactive intraoperative exploration for residual disease using contrast‐enhanced ultrasonography.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Soma et al. (2026) studied this question.

synapsesocial.com/papers/6996a818ecb39a600b3ee845https://doi.org/10.1002/ags3.70200
Ask AI
Helpful
Bookmark
Share
View Full Paper